Maria Antonietta Aloe Spiriti

Maria Antonietta Aloe Spiriti

Auto-generated profile, based on publicly available information

Maria Antonietta Aloe Spiriti

Sapienza University

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1990 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
GVG. Visani
G. Visani
CFC. Finelli
C. Finelli
UCU. Castelli
U. Castelli
MPM. C. Petti
M. C. Petti
PRP. Ricci
P. Ricci
STS. Tura
S. Tura

20 July 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MVMaria Teresa Voso
Maria Teresa Voso
SFSusanna Fenu
Susanna Fenu
RLRoberto Latagliata
Roberto Latagliata
Francesco BuccisanoFrancesco Buccisano
Francesco Buccisano
APAlfonso Piciocchi
Alfonso Piciocchi
Adriano VendittiAdriano Venditti
Adriano Venditti
Purpose: The definition of disease-specific prognostic scores plays a fundamental role in the treatment decision-making process in myelodysplastic syndrome (MDS), a group of myeloid disorders characterized by a heterogeneous clinical behavior. Patients and Methods: We applied the recently published Revised International Prognostic Scoring System (IPSS-R) to 380 patients with MDS, registered in an Italian regional database, recruiting patients from the city of Rome (Gruppo Romano Mielodisplasie). Patients were selected based on the availability of IPSS-R prognostic factors, including complete peripheral-blood and bone marrow counts, informative cytogenetics, and follow-up data. Results: We validated the IPSS-R score as a significant predictor of overall survival (OS) and leukemia-free survival (LFS) in MDS (P < .001 for both). When comparing the prognostic value of the International Prognostic Scoring System (IPSS), WHO Prognostic Scoring System (WPSS), and IPSS-R, using the Cox regression model and the likelihood ratio test, a significantly higher predictive power for LFS and OS became evident for the IPSS-R, compared with the IPSS and WPSS (P < .001 for both). The multivariate analysis, including IPSS, WPSS, age, lactate dehydrogenase, ferritin concentration, Eastern Cooperative Oncology Group performance status, transfusion dependency, and type of therapy, confirmed the significant prognostic value of IPSS-R subgroups for LFS and OS. Treatment with lenalidomide and erythropoiesis-stimulating agents was shown to be an independent predictor of survival in the multivariate analysis. Conclusion: Our data confirm that the IPSS-R is an excellent prognostic tool in MDS in the era of disease-modifying treatments. The early recognition of patients at high risk of progression to aggressive disease may optimize treatment timing in MDS.

4 February 2015 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
LFLuana Fianchi
Luana Fianchi
Livio PaganoLivio Pagano
Livio Pagano
APAlfonso Piciocchi
Alfonso Piciocchi
ACAnna Candoni
Anna Candoni
Gianluca GaidanoGianluca Gaidano
Gianluca Gaidano
MVMaria Teresa Voso
Maria Teresa Voso
Therapy‐related myeloid neoplasms (t‐MN) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. We report data on 277 t‐MN patients, recruited between 1999 and 2013 by the Italian Network on Secondary Leukemias (104 retrospectively and 173 prospectively registered). Median age at t‐MN diagnosis was 64 years (range, 21–87). Most frequent primary malignancies (PMs) were lymphoproliferative diseases and breast cancer. One hundred and thirty‐three patients had received chemotherapy (CHT), 43 patients radiotherapy (RT), and 101 patients combined CHT/RT for PM. Median time between cytotoxic treatment and t‐MN was 5.7 years, with t‐MN following RT alone associated with significantly longer latency, compared to CHT or combined CHT/RT (mean, 11.2 vs. 7.1 years, P = 0.0005). The addition of topoisomerase‐II inhibitors to alkylating agents was associated with shorter latency compared to alkylating agents alone (median, 6 vs. 8.4 years, P = 0.02). Median survival was 14.6 months from t‐MN diagnosis, and was significantly longer in patients treated with allogeneic stem cell transplantation. Significant factors for survival at the multivariable analysis included age, adverse karyotype, and degree of anemia. Our data underline the prognostic importance of karyotype and age in t‐MN, similar to de novo acute myeloid leukemia. Treatment approaches should not preclude the use of conventional treatments for younger t‐MN patients, including allogeneic stem cell transplantation as potentially curative approach. Am. J. Hematol. 90:E80–E85, 2015.

11 February 2010 in Cancer
Verified
Journal Article
Closed access
PDF file
PMPellegrino Musto
Pellegrino Musto
LMLuca Maurillo
Luca Maurillo
ASAlessandra Spagnoli
Alessandra Spagnoli
AGAntonella Gozzini
Antonella Gozzini
FRFlavia Rivellini
Flavia Rivellini
Valeria SantiniValeria Santini
Valeria Santini

1 January 2008 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
MCMaria Christina Cox
Maria Christina Cox
INItalo Nofroni
Italo Nofroni
LRLuigi Ruco
Luigi Ruco
RARachele Amodeo
Rachele Amodeo
AFAntonella Ferrari
Antonella Ferrari
MAMaria Antonietta Aloe-Spiriti
Maria Antonietta Aloe-Spiriti
The prognostic value of absolute lymphocytic count (ALC), has been a recent matter of debate in non-Hodgkin-lymphoma (NHL). We assessed prospectively the value of ALC at diagnosis and also after the completion of immuno-chemotherapy in 101 diffuse-large-B-cell-lymphoma (DLBCL). Analysis of prognostic factors with respect to overall survival (OS), event free survival (EFS) and progression free survival (PFS) was done by two-tailed log-rank test. The ALC cut-off value was calculated as <0.84 x 10(9)/L at diagnosis: this was a strong negative prognostic factor for OS (p = 0.0004), EFS (p < 0.00001) and PFS (p < 0.00001) and in multivariate analysis was independent from the revised-international-prognostic-index (R-IPI). ALC after chemo-immunotherapy was not of prognostic value. As R-IPI and ALC < 0.84 x 10(9)/L, were the factors better discriminating poor prognosis, a new trichotomous score (ALC/R-IPI) was built up: (1) low risk: R-IPI = very good or good and ALC < 0.84 x 10(9)/L; (2) intermediate risk: patients with at least one risk factor (R-IPI = poor or ALC < 0.84 x 10(9)/L). (3) high risk: patients with both risk factors. This new prognostic score was highly significant in univariate analysis for OS (p = 0.0002), EFS (p < 0.00001) and PFS (p < 0.00001). In multivariate analysis ALC/R-IPI was the most predictive factor for OS (OR = 2.954; p = 0.002) and EFS (OR = 2.381; p < 0.00001) and the only predictive factor for PFS (OR = 4.018; p < 0.00001). Our data, show that ALC at diagnosis has a strong prognostic relevance and is independent from the R-IPI. The new score including both values proved the most powerful predictor at multivariate analysis.

1 August 2002 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
MVMauro Vairano
Mauro Vairano
DCDello Russo Cinzia
Dello Russo Cinzia
GPGiacomo Pozzoli
Giacomo Pozzoli
ABAlessandra Battaglia
Alessandra Battaglia
GSGiovanni Scambia
Giovanni Scambia
PNPierluigi Navarra
Pierluigi Navarra